Bloodwork Before Starting Ipamorelin

Why Baseline Bloodwork Matters for Ipamorelin

Ipamorelin is a selective GHS-R1a agonist, meaning it drives growth hormone release from the anterior pituitary without dragging cortisol, prolactin, or ACTH along with it. That selectivity is precisely why baseline bloodwork matters: you need a clean snapshot of the GH/IGF-1 axis before amplifying it. Without pre-protocol labs, there is no way to distinguish a therapeutic response from a pre-existing abnormality. Growth hormone opposes insulin at the tissue level, so fasting glucose deserves attention before you start increasing GH pulse amplitude. And because ipamorelin’s hallmark is what it does not disturb — cortisol and prolactin — confirming those values are normal at baseline protects that claim for your own biology. A selective secretagogue deserves selective monitoring. The baseline panel is where that starts.

What to Test Before Starting

Four biomarkers form the core of your pre-ipamorelin baseline panel, each tied to the specific axis this peptide acts on.

IGF-1 is the single most important draw. IGF-1 reflects cumulative GH signaling over the preceding weeks, and ipamorelin will raise it. If your baseline IGF-1 is already in the upper quartile of the reference range, the therapeutic window narrows and the risk of pushing into supraphysiologic territory increases. Starting without this number means flying blind on the very axis you are modulating.

Fasting Glucose establishes your insulin sensitivity before GH begins opposing it. Growth hormone shifts substrate utilization toward lipolysis and away from glucose uptake. If fasting glucose is already borderline, that shift may tip into sustained hyperglycemia. A pre-protocol fasting glucose between 70 and 99 mg/dL provides the clearance you need. Values above 100 mg/dL warrant a conversation with your provider before proceeding.

Cortisol should be drawn as a morning serum sample. Ipamorelin’s defining feature is that it does not elevate cortisol, but that distinction only matters if you know where cortisol sits before you start. An elevated baseline cortisol points to a separate HPA axis issue that will confound your monitoring.

Prolactin completes the panel. Like cortisol, ipamorelin should leave prolactin untouched. A normal baseline value confirms the pituitary is not under pressure from a microadenoma or medication effect, either of which would change the risk calculus of adding a secretagogue.

What to Retest and When

At 4 weeks, retest GH. This is the earliest timepoint where you can confirm that ipamorelin is doing what it is supposed to do — increasing the amplitude of GH pulses. A serum GH draw taken 30 to 60 minutes after your usual injection provides the clearest signal. If GH has not moved from baseline, the dose, injection timing, or reconstitution may need revisiting.

At 8 weeks, retest IGF-1. Because IGF-1 integrates weeks of GH signaling, testing it earlier produces noise. An 8-week draw captures the downstream effect of sustained GH elevation and tells you whether the axis is responding proportionally. IGF-1 rising above the reference range at this point is a signal to reduce dose, not continue.

Fasting glucose, cortisol, and prolactin should be retested alongside the 8-week IGF-1 draw. Glucose confirms that insulin sensitivity has not deteriorated. Cortisol and prolactin should remain at baseline; any movement in either warrants investigation independent of ipamorelin, since the peptide itself should not be responsible.

Discuss all results with your prescribing provider before adjusting dose or continuing beyond the initial protocol period.

Red Flags — When to Pause and Retest

Stop dosing and contact your provider if labs reveal fasting glucose above 126 mg/dL, IGF-1 above the reference range, or any unexpected rise in cortisol or prolactin. Active malignancy and untreated pituitary disorders are absolute contraindications — if either is discovered during monitoring, ipamorelin must be discontinued immediately. If you are taking glucocorticoids, be aware they may blunt the GH response and complicate interpretation. Somatostatin analogs directly oppose ipamorelin’s mechanism and make concurrent use contraindicated.

How This Fits Your Broader Protocol

Ipamorelin is frequently combined with CJC-1295 or other GHRH analogs in growth hormone optimization stacks. If you are running a combination protocol, the same baseline panel applies, but monitoring frequency may need to increase. Review the full contraindication profile before starting, and run any concurrent medications through the interaction checker to flag conflicts before your first injection.